scispace - formally typeset
B

Barbara Ruggeri

Researcher at King's College London

Publications -  56
Citations -  2176

Barbara Ruggeri is an academic researcher from King's College London. The author has contributed to research in topics: Autism spectrum disorder & Autism. The author has an hindex of 22, co-authored 52 publications receiving 1740 citations. Previous affiliations of Barbara Ruggeri include University of Camerino & University of London.

Papers
More filters
Journal ArticleDOI

KLB is associated with alcohol drinking, and its gene product β-Klotho is necessary for FGF21 regulation of alcohol preference

Gunter Schumann, +149 more
TL;DR: It is shown that brain-specific β-Klotho KO mice have an increased alcohol preference and that FGF21 inhibits alcohol drinking by acting on the brain, suggesting that a liver–brain endocrine axis may play an important role in the regulation of alcohol drinking behavior and provide a unique pharmacologic target for reducing alcohol consumption.
Journal ArticleDOI

The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders

Eva Loth, +71 more
- 23 Jun 2017 - 
TL;DR: LEAP is to date the largest multi-centre, multi-disciplinary observational study worldwide that aims to identify and validate stratification biomarkers for ASD and is expected to enable it to confirm, reject and refine current hypotheses of neurocognitive/neurobiological abnormalities.
Journal ArticleDOI

Biomarkers in autism spectrum disorder: the old and the new

TL;DR: Biomarker research has great heuristic potential in targeting autism diagnosis and treatment and will eventually merge with novel biomarkers identified using unbiased genomic, epigenomic, transcriptomic, proteomic and metabolomic methods, to generate multimarker panels.
Journal ArticleDOI

The EU-AIMS Longitudinal European Autism Project (LEAP): Clinical characterisation

Tony Charman, +72 more
- 23 Jun 2017 - 
TL;DR: The established phenotypic heterogeneity in ASD is well captured in the LEAP cohort, with only minimal to moderate site differences on core clinical and cognitive measures.